Cancer Biologics Market, By Drug (Monoclonal antibodies, Cell Therapies, Recombinant proteins & cytokines, Cancer Vaccines, and Oncolytic viruses), By Application, By Mechanism, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV4918
|
Published Date
March 2026
|
Pages
382
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Cancer Biologics Market size was valued at US$ 52,610.68 Million in 2025, expanding at a CAGR of 8.71% from 2026 to 2033.
Cancer biologics are an advanced class of therapeutics derived from living organisms, including proteins, antibodies, and cells, designed to prevent, treat, or manage cancer with greater precision than traditional therapies. Unlike conventional treatments, which can affect both healthy and cancerous cells, biologics specifically target tumor cells. Key types include monoclonal antibodies, cancer vaccines, recombinant proteins, and other biologically engineered molecules. These therapies function by enhancing the body’s immune response, inhibiting tumor growth signals, or directly attacking cancer cells, often providing effective treatment with fewer side effects compared to standard chemotherapy or radiation.
Globally, approximately one in five people will develop cancer in their lifetime, and incidence is expected to rise in the coming years due to population growth and ageing. The cancer biologics market is expanding within this broader healthcare context, driven by the increasing burden of the disease and the need for advanced, targeted treatment options. According to the World Health Organization (WHO) and its cancer research arm, the International Agency for Research on Cancer (IARC), there were around 20million new cancer cases and nearly 9.7million cancer-related deaths worldwide in 2022. In response, governments and public health authorities are increasingly incorporating innovative therapeutic modalities, including biologics, into national cancer control strategies to improve treatment precision, clinical outcomes, and overall patient care.
Cancer Biologics Market- Market Dynamics
Rising Regulatory Approvals and Growing Clinical Adoption of Biologic Therapies
Regulatory authorities across major healthcare markets are increasingly approving biologic therapies, supporting their integration into modern cancer treatment protocols. Streamlined regulatory frameworks and faster review processes are enabling healthcare providers to adopt advanced biologic medicines more readily in oncology care. For example, according to the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research approved 55 novel drugs in 2023, with oncology remaining one of the most active areas for biologic and targeted therapies. Leading pharmaceutical companies, including Merck & Co. and Bristol Myers Squibb, continue to expand their oncology biologic pipelines with immunotherapy agents such as Keytruda and Opdivo, reflecting growing clinical acceptance of biologic-based cancer treatments. Collectively, rising regulatory approvals and increasing clinical adoption are driving innovation in oncology care, improving patient access to cutting-edge therapies, and encouraging sustained investment in the development of advanced cancer treatments.
Cancer Biologics Market- Segmentation Analysis:
The Global Cancer Biologics Market is segmented on the basis of Drug, Application, Mechanism, End User, and Region.
Among the three mechanism categories, targeted immune modulation is expected to play a pivotal role in the cancer biologics market. This growth is largely driven by the increasing adoption of immunotherapy strategies that enhance the immune system’s ability to recognize and destroy cancer cells. Therapies such as immune checkpoint inhibitors have shown substantial clinical benefits across multiple cancer types, including lung cancer, melanoma, and renal cancer. Regulatory data highlight the expanding role of immune-based biologics: a cross-national review reported that over 80 clinical indications for immune checkpoint inhibitors have been approved across major markets, covering approximately 20 cancer types, with many granted as first-line or combination therapies. Furthermore, the Cancer Research Institute (CRI) notes that more than 120 immunotherapy approvals were granted globally between 2011 and 2024, with immune checkpoint inhibitors representing the largest share. These trends underscore the strong clinical acceptance of targeted immune modulation, driven by its ability to provide durable responses and improve survival outcomes in several cancers.
Based on drug type, monoclonal antibodies are projected to experience significant growth in the cancer biologics market. Their ability to selectively target specific proteins on cancer cells enhances therapeutic efficacy while minimizing damage to healthy tissues. Monoclonal antibodies are widely employed across cancers such as breast, lung, and colorectal cancer, supporting their growing clinical adoption globally. Analysis of FDA biologic approvals in 2024 shows that 13 monoclonal antibodies received regulatory authorization, several of which are indicated for oncology. A notable example is Keytruda, developed by Merck & Co., which generated approximately $29.48billion in global sales in 2024, making it one of the leading oncology biologic therapies worldwide.
Cancer Biologics Market- Geographical Insights
Geographically, the cancer biologics market exhibits notable regional differences shaped by healthcare infrastructure, research capabilities, and treatment adoption rates. North America is expected to maintain a leading position in the market, supported by advanced healthcare systems, strong government-backed research programs, and a well-established regulatory framework that accelerates the development and approval of innovative biologic cancer therapies. The presence of major biotechnology and pharmaceutical companies, coupled with extensive clinical research activity, further drives the adoption of biologic-based oncology treatments across the region. Global statistics also underscore the growing need for such therapies: according to the American Cancer Society, there were approximately 20million new cancer cases and 9.7million cancer-related deaths worldwide in 2022, highlighting the pressing demand for advanced treatment options.
Within North America, the United States is a key market contributor due to its large patient population and robust biomedical research ecosystem. Data from the Centers for Disease Control and Prevention (CDC) via the United States Cancer Statistics program report 1,851,238 new cancer cases in 2022 and 613,349 cancer-related deaths in 2023, emphasizing the substantial need for innovative cancer therapeutics. Collectively, the high cancer burden, supportive government initiatives, advanced healthcare infrastructure, and strong research investment position North America, particularly the U.S., as a major driver of growth in the cancer biologics market.
India Cancer Biologics Market- Country Insights
India is gradually emerging as a significant market for cancer biologics, driven by a rising cancer burden, expanding healthcare infrastructure, and increasing emphasis on biotechnology innovation. According to the Indian Council of Medical Research (ICMR) through the National Cancer Registry Programme (NCRP), approximately 1.46million new cancer cases were reported in 2022, with projections estimating around 1.57million cases by 2025, underscoring the growing demand for advanced treatment options such as biologic therapies. Government initiatives are also bolstering oncology care across the country. For example, the Ministry of Health and Family Welfare implements the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), which focuses on enhancing cancer screening, diagnosis, and treatment infrastructure at the state level.
Combined with the increasing participation of domestic biopharmaceutical companies, these factors are strengthening India’s position in the cancer biologics market. Continued investment in biotechnology research, along with the expansion of biosimilar production, is expected to improve access to advanced cancer therapies and support the gradual growth and development of the country’s biologics landscape.
Cancer Biologics Market- Competitive Landscape:
The cancer biologics market is highly competitive and innovation-driven, characterized by strategic alliances, mergers and acquisitions, and strong R&D initiatives. The market landscape is shaped by numerous global pharmaceutical and biotechnology companies focused on developing advanced biologic therapies for oncology. Market players emphasize research and innovation to deliver targeted treatments, including monoclonal antibodies, immune checkpoint inhibitors, and cell-based therapies, aimed at improving clinical outcomes for cancer patients. Leading organizations such as F. Hoffmann-La Roche Ltd, Merck & Co., and Amgen Inc. hold prominent positions due to their extensive oncology pipelines and continued focus on biologic innovation. Additionally, companies like AstraZeneca and Pfizer Inc. are actively expanding their immuno-oncology and biologics research capabilities. Collectively, these efforts foster a dynamic, innovation-oriented competitive environment where continuous product development and collaborative research drive the advancement of modern cancer therapies.
Recent Developments:
- In February 2026, Innovent Biologics partnered with Eli Lilly to jointly develop oncology and immunology therapies, with Innovent leading early-stage development in China and Lilly managing global commercialization outside Greater China. This collaboration strengthens the global cancer biologics pipeline by combining regional expertise with international reach, expanding patient access to innovative treatments.
- In June 2025, Alvotech and Dr. Reddy’s Laboratories teamed up to co-develop, manufacture, and commercialize a pembrolizumab biosimilar. Leveraging Alvotech’s R&D and manufacturing capabilities alongside Dr. Reddy’s global commercialization network, the partnership aims to enhance worldwide accessibility to this key cancer immunotherapy, supporting broader patient access and affordability.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CANCER BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- F. Hoffmann La Roche Ltd
- Novartis AG
- Merck & Co.
- Bristol Myers Squibb
- Johnson & Johnson
- Eli Lilly and Company
- Sanofi
- AbbVie Inc.
- Amgen Inc.
- BioNTech
- Genmab
- Incyte Corporation
- Roche
- Bayer
- Others
GLOBAL CANCER BIOLOGICS MARKET, BY DRUG- MARKET ANALYSIS, 2020 - 2033
- Monoclonal antibodies
- Cell Therapies
- Recombinant proteins & cytokines
- Cancer Vaccines
- Oncolytic viruses
GLOBAL CANCER BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Hematologic cancers
- Breast Cancer
- Lung Cancer
- Colorectal and other solid tumors
GLOBAL CANCER BIOLOGICS MARKET, BY MECHANISM- MARKET ANALYSIS, 2020 - 2033
- Targeted immune modulation
- Tumor specific cell based therapies
- Angiogenesis and growth factor inhibitors
- Others
GLOBAL CANCER BIOLOGICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Clinics
- Research Institutes
- Others
GLOBAL CANCER BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Cancer Biologics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Cancer Biologics Market Snippet by Drug
2.1.2. Cancer Biologics Market Snippet by Application
2.1.3. Cancer Biologics Market Snippet by Mechanism
2.1.4. Cancer Biologics Market Snippet by End User
2.1.5. Cancer Biologics Market Snippet by Country
2.1.6. Cancer Biologics Market Snippet by Region
2.2. Competitive Insights
3. Cancer Biologics Key Market Trends
3.1. Cancer Biologics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Cancer Biologics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Cancer Biologics Market Opportunities
3.4. Cancer Biologics Market Future Trends
4. Cancer Biologics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Cancer Biologics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Cancer Biologics Market Landscape
6.1. Cancer Biologics Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Cancer Biologics Market – By Drug
7.1. Overview
7.1.1. Segment Share Analysis, By Drug, 2025 & 2033 (%)
7.1.2. Monoclonal antibodies
7.1.3. Cell Therapies
7.1.4. Recombinant proteins & cytokines
7.1.5. Cancer Vaccines
7.1.6. Oncolytic viruses
8. Cancer Biologics Market – By Application
8.1. Overview
8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
8.1.2. Hematologic cancers
8.1.3. Breast Cancer
8.1.4. Lung Cancer
8.1.5. Colorectal and other solid tumors
9. Cancer Biologics Market – By Mechanism
9.1. Overview
9.1.1. Segment Share Analysis, By Mechanism, 2025 & 2033 (%)
9.1.2. Targeted immune modulation
9.1.3. Tumor specific cell based therapies
9.1.4. Angiogenesis and growth factor inhibitors
9.1.5. Others
10. Cancer Biologics Market – By End User
10.1. Overview
10.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
10.1.2. Hospitals
10.1.3. Clinics
10.1.4. Research Institutes
10.1.5. Others
11. Cancer Biologics Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Cancer Biologics Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Cancer Biologics Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Cancer Biologics Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Cancer Biologics Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Cancer Biologics Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Cancer Biologics Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. F. Hoffmann La Roche Ltd
12.2.2. Novartis AG
12.2.3. Merck & Co.
12.2.4. Bristol Myers Squibb
12.2.5. Johnson & Johnson
12.2.6. Eli Lilly and Company
12.2.7. Sanofi
12.2.8. AbbVie Inc.
12.2.9. Amgen Inc.
12.2.10. BioNTech
12.2.11. Genmab
12.2.12. Incyte Corporation
12.2.13. Roche
12.2.14. Bayer
12.2.15. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CANCER BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- F. Hoffmann La Roche Ltd
- Novartis AG
- Merck & Co.
- Bristol Myers Squibb
- Johnson & Johnson
- Eli Lilly and Company
- Sanofi
- AbbVie Inc.
- Amgen Inc.
- BioNTech
- Genmab
- Incyte Corporation
- Roche
- Bayer
- Others
GLOBAL CANCER BIOLOGICS MARKET, BY DRUG- MARKET ANALYSIS, 2020 - 2033
- Monoclonal antibodies
- Cell Therapies
- Recombinant proteins & cytokines
- Cancer Vaccines
- Oncolytic viruses
GLOBAL CANCER BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Hematologic cancers
- Breast Cancer
- Lung Cancer
- Colorectal and other solid tumors
GLOBAL CANCER BIOLOGICS MARKET, BY MECHANISM- MARKET ANALYSIS, 2020 - 2033
- Targeted immune modulation
- Tumor specific cell based therapies
- Angiogenesis and growth factor inhibitors
- Others
GLOBAL CANCER BIOLOGICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Clinics
- Research Institutes
- Others
GLOBAL CANCER BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
